AKT1 and metabolic syndrome: To elucidate the mechanism of SHC in regulating dyslipidemia and anti-inflammation, this study identified that SHC’s mechanism of action in intervening with AS primarily involves the lipid and AS signaling pathway, the PI3K-Akt signaling pathway, and the MAPK signaling pathway, among others, through network pharmacology.